EGFR and non-small cell lung carcinoma: Between January 2019 and November 2020, 1,474 patients with NSCLC (any stage) were included in 16 sites across France (five sites), Germany (five sites), Italy (five sites) and Belgium (one site), with each site processing approximately 100 paired samples for prospective EGFR variant analysis.